Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Merry Peckham; Horace J. Spencer; Shorabuddin Syed; William B. Armstrong; Donald Gregory Farwell; Thomas J. Gal; David Goldenberg; Marika D. Russell; Roberto N. Solis; Deanne King; Brendan C. Stack

doi:10.1002/jso.26825

Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Merry Peckham, Horace J. Spencer, Shorabuddin Syed, William B. Armstrong, Donald Gregory Farwell, Thomas J. Gal, David Goldenberg, Marika D. Russell, Roberto N. Solis, Deanne King, Brendan C. Stack

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Objective: To investigate a possible link between breast and thyroid cancer. Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics. Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50–5.18). Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

Original language	English
Pages (from-to)	1211-1217
Number of pages	7
Journal	Journal of Surgical Oncology
Volume	125
Issue number	8
DOIs	https://doi.org/10.1002/jso.26825
State	Published - Jun 15 2022

Bibliographical note

Funding Information:
This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI.

Funding Information:
This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI.

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

breast cancer
epidemiology
thyroid cancer

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jso.26825

Cite this

@article{7573a7331bf64460a6274c116203ca0b,

title = "Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network",

abstract = "Objective: To investigate a possible link between breast and thyroid cancer. Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics. Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50–5.18). Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.",

keywords = "breast cancer, epidemiology, thyroid cancer",

author = "Merry Peckham and Spencer, {Horace J.} and Shorabuddin Syed and Armstrong, {William B.} and Farwell, {Donald Gregory} and Gal, {Thomas J.} and David Goldenberg and Russell, {Marika D.} and Solis, {Roberto N.} and Deanne King and Stack, {Brendan C.}",

note = "Funding Information: This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI. Funding Information: This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI. Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = jun,

day = "15",

doi = "10.1002/jso.26825",

language = "English",

volume = "125",

pages = "1211--1217",

number = "8",

}

TY - JOUR

T1 - Breast and thyroid cancer

T2 - A multicenter study with Accrual to Clinical Trials Network

AU - Peckham, Merry

AU - Spencer, Horace J.

AU - Syed, Shorabuddin

AU - Armstrong, William B.

AU - Farwell, Donald Gregory

AU - Gal, Thomas J.

AU - Goldenberg, David

AU - Russell, Marika D.

AU - Solis, Roberto N.

AU - King, Deanne

AU - Stack, Brendan C.

N1 - Funding Information: This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI. Funding Information: This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI. Publisher Copyright: © 2022 Wiley Periodicals LLC.

PY - 2022/6/15

Y1 - 2022/6/15

N2 - Objective: To investigate a possible link between breast and thyroid cancer. Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics. Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50–5.18). Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

AB - Objective: To investigate a possible link between breast and thyroid cancer. Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics. Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50–5.18). Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

KW - breast cancer

KW - epidemiology

KW - thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85125051591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125051591&partnerID=8YFLogxK

U2 - 10.1002/jso.26825

DO - 10.1002/jso.26825

M3 - Article

C2 - 35195923

AN - SCOPUS:85125051591

SN - 0022-4790

VL - 125

SP - 1211

EP - 1217

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 8

ER -

Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this